Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB25FYX09
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $125,532
Award facts
- Contract value 100% obligated
- $125,531.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $125,531.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. This firm fixed-price delivery order, issued on July 11, 2025, with an ultimate completion date of August 1, 2025, represents a direct procurement with no set-aside designation. The award falls under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which authorizes the agency to issue delivery orders for pharmaceutical products supporting Department of Defense healthcare facilities.
EXPAREL is a local anesthetic used in surgical and medical settings to provide prolonged pain relief. DMS Pharmaceutical Group's extensive federal contract history demonstrates established capability in delivering specialized pharmaceutical products, including injectable medications and controlled substances, to military health facilities nationwide. The company's procurement through the DLA's pharmaceutical supply framework reflects its critical role in the federal pharmaceutical supply chain, ensuring availability of branded pharmaceutical products essential to DoD medical operations and patient care.
Quick answers
Who was awarded contract SPE2DB25FYX09?
SPE2DB25FYX09 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 11, 2025.
How much is contract SPE2DB25FYX09 worth?
The government has obligated $125,532 on SPE2DB25FYX09.
Is contract SPE2DB25FYX09 an order under another contract?
Yes. SPE2DB25FYX09 is a delivery order under SPE2DB22D9133, an indefinite delivery contract.
Was contract SPE2DB25FYX09 competed?
The extent of competition for SPE2DB25FYX09 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award